One of the UM grant recipients is Dr. Soheila Karimi, professor of physiology and pathophysiology, Max Rady College of Medicine, and founding director of the Manitoba Multiple Sclerosis Research Centre. She and her team received $1,143,675 over five years to study what could one day be a new treatment for progressive multiple sclerosis (MS).
“MS happens when the body’s immune system attacks and damages myelin, a protective layer around nerve fibers of the brain and spinal cord. My research group has identified that Neuregulin-1, which is an important protein for proper function of the brain and spinal cord, is depleted in MS lesions. We have strong evidence that Neuregulin-1 holds promise as a potential treatment to promote myelin repair in progressive MS when repair fails, resulting in increased neurological impairments,” said Karimi, who is also a researcher with the Children’s Hospital Research Institute of Manitoba (CHRIM).
Karimi’s project will evaluate Neuregulin-1 as a future treatment to prevent the progression of MS and support tissue repair. A new treatment is much needed, Karimi said, because Canada is home to the world’s highest prevalence of MS and current medications are minimally effective for the progressive phase of the disease.
“We are really hoping that this research will set the groundwork for conclusive findings which would justify going to clinical trials, especially for progressive MS, because there is a critical treatment gap,” Karimi said.
